Elanco Animal Health Reports First Quarter 2026 Results
Elanco reported Q1 2026 revenue of $1.37 billion, up 15% year-over-year, driven by 10% organic constant currency growth and strong performance across its pet health and farm animal segments. The company raised its full-year 2026 guidance, now targeting revenue of $5.01 billion to $5.09 billion and Adjusted EBITDA of $975 million to $1.005 billion, while improving its year-end net leverage ratio target to 3.0x-3.2x.
Key figures
- Eps
- 0.11
- Revenue
- 1371000000
- Guidance
- FY2026 revenue $5,010M-$5,085M, Adjusted EBITDA $975M-$1,005M, Adjusted EPS $1.03-$1.09
- Revenue Yoy
- 15%
- Adjusted eps
- 0.4
- Adjusted ebitda
- 334000000
- Organic cc growth
- 10%
- Net leverage ratio
- 3.5x
- Adjusted ebitda margin
- 24.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.